Certara CERT stock broke below its 200 day moving average on June 8, 2023. CERT stock is in a technical weak downtrend rating.
Certara Inc. is a leading provider of model-informed drug development and regulatory science services to the pharmaceutical and biotechnology industries. The company’s solutions include physiologically-based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), pharmacometric analysis, clinical trial simulation, and regulatory support. Certara’s technology and expertise are used by drug developers to optimize drug dosage, predict clinical outcomes, and accelerate drug development timelines. Additionally, the company provides software tools and training to support drug development teams in their modeling and simulation efforts.
John Gallagher, Certara’s CFO, is blamed for the stock decline after making disparaging comments about the company’s near-term prospects. In his remarks at the Jefferies Global Healthcare Conference, Gallagher said Certara is not completely immune to funding restrictions in the biotech sector. Gallagher commented on Q2 performance saying “We’re not fully insulated from some of the funding overhang” in the biotech industry as well as some of the slower pace of pharma investment. The lengthening of the salesThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... cycle, according to Gallagher, is being caused by the layoffs some of the company’s clients are experiencing.
